CONMED Q2 sales +14.6% to $317.7M, adj. EPS $0.83, raises FY guidance

CONMED Corp

2023-Q2 EPS reported $0.49 revenue$613,121,000

GAAP diluted EPS $0.43 vs loss of $5.65; adjusted diluted EPS $0.83, +9.2% YoY.
Revenue $317.7M (+14.6% as reported, +16.6% constant currency); acquisitions added ~400 bps.
Domestic sales +17.1%; International sales +11.7% as reported (+16.0% constant currency).
Orthopedic Surgery +17.1%, General Surgery +12.6% as reported.
FY 2023 revenue guidance raised to $1.230-1.260B; adjusted EPS guidance raised to $3.40-3.55.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

CONMED Corp reported second quarter ended June 30, 2023 results: revenue $317.7 million, net income $13,732, EPS $0.43. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: $317.7 million
Net income: $13,732
EPS: $0.43
Guidance: raised
Result: reported results

Exact text from the filing

Florida, July 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights · Sales of $317.7 million increased 14.6% year over year as reported and 16.6% in constant currency. Acquisitions contributed approximately 400 basis points of growth. · Domestic revenue increased 17.1%

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

CONMED Corp filing history →

Source: SEC EDGAR

accession 0001174947-23-000915

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.